Lantern Pharma Inc (LTRN)vsBeiGene, Ltd. (ONC)
LTRN
Lantern Pharma Inc
$2.51
-3.46%
HEALTHCARE · Cap: $35.60M
ONC
BeiGene, Ltd.
$327.21
-0.98%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 8.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).
LTRN
Avoid16
out of 100
Grade: F
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LTRN.
Margin of Safety
+81.1%
Fair Value
$1857.02
Current Price
$327.21
$1529.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.1x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LTRN
The strongest argument for LTRN centers on Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : LTRN
The primary concerns for LTRN are Price/Book, Revenue Growth, EPS Growth.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
LTRN profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
LTRN carries more volatility with a beta of 2.29 — expect wider price swings.
ONC is growing revenue faster at 35.5% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (54/100 vs 16/100) and 35.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lantern Pharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?